PCM
VKTX icon

Penserra Capital Management’s Viking Therapeutics VKTX Stock Holding History

Penserra Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
6,142
+3,324
+118% +$107K ﹤0.01% 671
2026
Q1 		$91K Buy
2,818
+1,368
+94% +$44K ﹤0.01% 738
2025
Q4 		$51K Buy
+1,450
New +$51.4K ﹤0.01% 766
2025
Q3 		– Sell
-2,105
Closed -$55K – 1098
2025
Q2 		$55K Sell
2,105
-167
-7% -$4.4K ﹤0.01% 759
2025
Q1 		$54K Buy
2,272
+206
+10% +$6.51K ﹤0.01% 845
2024
Q4 		$83K Buy
2,066
+192
+10% +$10.9K ﹤0.01% 881
2024
Q3 		$118K Buy
1,874
+583
+45% +$34.2K ﹤0.01% 767
2024
Q2 		$68K Buy
+1,291
New +$84.6K ﹤0.01% 842

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Penserra Capital Management's VKTX Position: Q2 2026 in Review

Penserra Capital Management increased its Viking Therapeutics (VKTX) stake by 118% in Q2 2026, buying an estimated $107K and bringing the position to 6,142 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Penserra Capital Management first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Penserra Capital Management held 6,142 shares of Viking Therapeutics worth $239K as of Q2 2026.
  • Penserra Capital Management bought 3,324 Viking Therapeutics shares in Q2 2026, an estimated $107K.
  • Viking Therapeutics made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #671 holding.
  • Penserra Capital Management first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.